A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.

Saved in:

Bibliographic Details
Title:	A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.
Authors:	Curtin, Francois^1,2 (AUTHOR) fc@geneuro.com, Champion, Bernard³ (AUTHOR), Davoren, Peter⁴ (AUTHOR), Duke, Sally⁵ (AUTHOR), Ekinci, Elif I.⁶ (AUTHOR), Gilfillan, Chris⁷ (AUTHOR), Morbey, Claire⁸ (AUTHOR), Nathow, Thomas⁹ (AUTHOR), O'Moore‐Sullivan, Trisha¹⁰ (AUTHOR), O'Neal, David¹¹ (AUTHOR), Roberts, Adam¹² (AUTHOR), Stranks, Stephen¹³ (AUTHOR), Stuckey, Bronwyn¹⁴ (AUTHOR), Vora, Parind¹⁵ (AUTHOR), Malpass, Sam¹⁶ (AUTHOR), Lloyd, David¹⁶ (AUTHOR), Maëstracci‐Beard, Nicole¹ (AUTHOR), Buffet, Bénédicte¹ (AUTHOR), Kornmann, Gabrielle¹ (AUTHOR), Bernard, Corinne¹ (AUTHOR)
Source:	Diabetes, Obesity & Metabolism. Jul2020, Vol. 22 Issue 7, p1111-1121. 11p.
Database:	Academic Search Ultimate

Description
ISSN:	14628902
DOI:	10.1111/dom.14010